Two California-based companies are joining forces to advance molecular diagnostics for cancer. Cynvenio, a cancer diagnostics company focused on treatment and management through the genomic analysis of tumor cells in blood, has announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine. The two companies have agreed to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.
Under this agreement, Cynvenio will access multiple CollabRx products, including the Genetic Variant Annotation (GVA) Service, to offer clinically relevant data and reporting solutions with Cynvenio’s ClearID Breast Cancer and LiquidBiopsy genomic testing services. ClearID is a monitoring test for breast cancer survivors at high risk of disease recurrence. The ClearID blood test analyzes circulating tumor cells for cancer-associated genomic mutations which can be used to characterize disease status and available treatment options. Clinicians and researchers ordering genomic tests from Cynvenio will have the option to also choose GVA-based reporting on identified mutations that includes a summary of the clinical evidence for treatment planning, approved targeted therapies, relevant clinical trials for investigational therapies, and additional references for further research.
“A contextualized interpretation of sequencing results is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients,” says André de Fusco, CEO of Cynvenio. “CollabRx has developed a scalable process and software platform to provide key elements of the reporting solution that Cynvenio provides to aid physicians in the clinical interpretation of tumor-specific molecular profiles. We are pleased to be able to include GVA with our molecular testing services.” Learn more about ClearID Breast Cancer and GVA Service.
